EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy

Ulas Kumbasar, Erkan Dikmen, Zeliha Gunnur Dikmen iD, Ates Tenekeci iD, Ilgen Mender iD, Sergei Gryaznov iD, Burak Bilgin, Saadettin Kilickap

Cells · 2025

DOI: 10.3390/cells14130971 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Ulas Kumbasar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Faculty of Medicine, Hacettepe University, Ankara 06100, Türkiye. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy, Perioperative Care. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Nonetheless, deeper molecular understanding of NSCLC has resulted in novel therapeutic approaches, including targeted therapy and immunotherapy, which have improved patient prognosis and outcomes in recent years. Immune checkpoint inhibitors (ICIs), with or without chemotherapy, are now considered valuable components of treatment for NSCLC cases that do not have specific actionable genetic mutations. Patients with actionable genetic mutations are candidates for targeted therapies. The primary focus of this review is the rationale for using ICIs in the perioperative setting for patients with resectable NSCLC and in advanced disease settings. Furthermore, we compare the benefits of using ICIs with the challenges associated with their clinical implementation in resectable and advanced NSCLC. Finally, we emphasize the development of novel treatment strategies that potentially provide an optimal treatment choice for patients with advanced NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmunotherapyPerioperative CareHumansImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

NSCLCadjuvant therapyimmunotherapyneoadjuvant therapytargeted therapy

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Faculty of Medicine, Hacettepe University, Ankara 06100, Türkiye.
  • Department of Medical Biochemistry, Faculty of Medicine, Hacettepe University, Ankara 06100, Türkiye.
  • Department of Research and Development, MAIA Biotechnology, Inc., Chicago, IL 60606, USA.
  • Medical Oncology, Yildirim Beyazit University, Ankara 06800, Türkiye.
  • Medical Oncology, Liv Hospitals, Istinye University, Ankara 06800, Türkiye.

ORCID-Profile: Zeliha Gunnur Dikmen, Ates Tenekeci, Ilgen Mender, Sergei Gryaznov

Zitieren

APA

Kumbasar, U., Dikmen, E., Dikmen, Z. G., Tenekeci, A., Mender, I., Gryaznov, S., Bilgin, B., & Kilickap, S. (2025). Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy. Cells. https://doi.org/10.3390/cells14130971

Vancouver

Kumbasar U, Dikmen E, Dikmen ZG, Tenekeci A, Mender I, Gryaznov S, et al. Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy. Cells. 2025. doi:10.3390/cells14130971

BibTeX
@article{Kumbasar2025,
  author = {Kumbasar, Ulas and Dikmen, Erkan and Dikmen, Zeliha Gunnur and Tenekeci, Ates and Mender, Ilgen and Gryaznov, Sergei and Bilgin, Burak and Kilickap, Saadettin},
  title = {Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14130971}
}
Kostenlos starten →